Amicus Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $777.9 Mil.
During the past 12 months, Amicus Therapeutics's average Total Assets Growth Rate was 14.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.40% per year.
During the past 13 years, Amicus Therapeutics's highest 3-Year average Total Assets Growth Rate was 298.60%. The lowest was -25.60%. And the median was 15.30%.
The historical data trend for Amicus Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Amicus Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics (NAS:FOLD) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Amicus Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Amicus Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics (Amicus Therapeutics) Business Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 